The purpose of this study was to discuss the anti-tumor function of lysozyme (LZM) to laryngocarcinoma. The LZM distribution of regional lymph nodes incised from laryngocarcinoma patients in paraffin sections was observed by immunohistochemical technique. By the cell culture technique, autologus laryngocarcinoma cells were used as target cells to evaluate the tumoridical activity of MØ which were isolated from the regional lymph nodes of laryngocarcinoma patients. At the same time, ConA was added as control group. The supernatant of cell culture was collected after 24 hours to detect LZM content. The results indicated that the number of LPM in non-metastatic lymph nodes was significantly more than in metastatic lymph nodes (P < 0.01). The MØ isolated from patients' regional lymph nodes released LZM content and it's tumoridical activity to autologus tumor cells were significantly increased after adding ConA (P < 0.01). The LZM releasing content and tumoridical activity of MØ in non-metastatic lymph nodes were much more than metastatic lymph nodes (P < 0.05). The LZM content and tumoridical activity of MØ were analyzed with linearity relapsing statistics, it was positive linearity relation (r = 0.94, P < 0.01). All above suggests that the LZM of laryngocarcinoma patients is closely related to the anti-tumor function, it improves the tumoridical activity of MØ to autologus laryngocarcinoma cells and accelerates the death of laryngocarcinoma cells.